Comparison · NCT02303392-sae
Chronic Lymphocytic Leukemia (CLL) vs Non-Hodgkin Lymphoma (NHL): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Chronic Lymphocytic Leukemia (CLL) vs Non-Hodgkin Lymphoma (NHL): serious adverse events. Trial comparisons, record NCT02303392-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02303392-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.375 | 0.185 | 0.614 | wilson | |
| Risk in group 2 | 0.389 | 0.203 | 0.614 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0139 | -0.308 | 0.289 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.964 | 0.409 | 2.27 | log | |
| Odds ratio, group 1 over group 2 | 0.943 | 0.236 | 3.77 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Chronic Lymphocytic Leukemia (CLL) than on Non-Hodgkin Lymphoma (NHL) | 72 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Chronic Lymphocytic Leukemia (CLL) | Patients receive ibrutinib PO on days 8-28 of course 1 and on days 1-28 on subsequent courses and selinexor PO BID weekly on day 1 or bi-weekly on days 1 and 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Selinexor: Given PO~Ibrutinib: Given PO~Pharmacological Study: Correlative studies~Laboratory Biomarker Analysis: Correlative studies | 6 | 16 | EG000 |
| Group 2 | Non-Hodgkin Lymphoma (NHL) | Patients receive ibrutinib PO on days 8-28 of course 1 and on days 1-28 on subsequent courses and selinexor PO BID weekly on day 1 or bi-weekly on days 1 and 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Selinexor: Given PO~Ibrutinib: Given PO~Pharmacological Study: Correlative studies~Laboratory Biomarker Analysis: Correlative studies | 7 | 18 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All patients must be carefully monitored for AEs, including clinical laboratory tests. AEs should be assessed in terms of their seriousness, intensity, and relationship to the study drug. For consistency, events are to be graded using the CTCAE version 4.0 from start of study to completion for up to 4 years.
Source ClinicalTrials.gov
Trial
- Title
- Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
- NCT number
- NCT02303392
- Phases
- PHASE1
- Conditions
- Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Interventions
- Selinexor, Ibrutinib, Pharmacological Study, Laboratory Biomarker Analysis
- Lead sponsor
- Jennifer Woyach
- Results first posted
- 2025-06-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02303392?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02303392-sae